THERMAC trial

Breast cancer is the most common type of cancer amongst women in the Netherlands. Each year almost 15,000 new patients get diagnosed with breast cancer. Due to the introduction of the screening program half of the detected breast tumors are ≤ 2 cm. Patients with these type of tumors could presumably be treated less invasive. Previous studies have shown that thermal ablation could be a safe and effective alternative to surgical excision. The advantage of thermal ablation is that it can be performed under local anesthetics and thus no surgical procedure, general anesthesia and hospital admission will be necessary. We expect that this will lead to a better health related quality of life and a better cosmetic outcome. We will continue the development of this very patient-friendly treatment of breast cancer. However, the research regarding this treatment is very costly. We are happy to be given partial subsidy for our research by Stichting Coolsingel in December 2017 and by Team Westland (www.teamwestland.nl), and Stichting BOF in October 2019. More on this project can be found on our News page.

The systematic review on this topic can be found on the website of the journal Clinical Breast Cancer. The study is registered at the Dutch trial register (NTR).

Related Projects